US 12,029,731 B2
Acyl benzo[d]thiazol-2-amine and their methods of use
Jeffery Claude Pelletier, Lafayette Hill, PA (US); Allen B. Reitz, Lansdale, PA (US); and Jay Edward Wrobel, Lawrenceville, NJ (US)
Assigned to Biohaven Therapeutics Ltd., New Haven, CT (US)
Appl. No. 16/323,850
Filed by Biohaven Pharmaceutical Holding Company Ltd., New Haven, CT (US)
PCT Filed Aug. 10, 2017, PCT No. PCT/US2017/046184
§ 371(c)(1), (2) Date Feb. 7, 2019,
PCT Pub. No. WO2018/031707, PCT Pub. Date Feb. 15, 2018.
Claims priority of provisional application 62/373,091, filed on Aug. 10, 2016.
Prior Publication US 2019/0209532 A1, Jul. 11, 2019
Int. Cl. C07K 5/00 (2006.01); A61K 31/428 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 277/82 (2006.01); C07D 277/84 (2006.01)
CPC A61K 31/428 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 277/82 (2013.01); C07D 277/84 (2013.01)] 3 Claims
 
1. A compound having a structure according to formula (IX):

OG Complex Work Unit Chemistry
including pharmaceutically acceptable salts thereof, wherein:
R1, R2 and R3 are each independently hydrogen or halogen;
R4 is hydrogen;
R14a and R14b are hydrogen;
R15 is C1-C6 alkyl;
R17a and R17b are hydrogen;
R19a is C1-C6 alkyl; and
R19b is hydrogen.